News | May 28, 2007

MR Focused Ultrasound Relieves Fibroid Symptoms in Women

May 29, 2007 – A noninvasive ultrasound procedure effectively shrinks uterine fibroids and significantly relieves fibroid-related symptoms in women, according to the results of a multicenter clinical trial reported in the June issue of the journal Radiology. Magnetic resonance-guided, focused ultrasound surgery (MRgFUS) allows radiologists to precisely target fibroids without harming healthy surrounding tissue.

“This treatment immediately stops blood flow in the treated fibroid tissue, which results in a significant, sustained decrease in symptoms for up to 12 months,” said the study’s lead author, Fiona M. Fennessy, M.D., Ph.D., assistant professor of radiology at Harvard Medical School and staff radiologist at Brigham and Women’s Hospital in Boston.

Uterine fibroids are benign growths of the muscle inside the uterus. According to the National Institutes of Health, at least 25 percent of women in the United States age 25 to 50 suffer from symptomatic uterine fibroids. Fibroid symptoms can include excessive menstrual bleeding, enlarged uterine size, frequent urination, pelvic pressure or pain and infertility. According to the National Women’s Health Information Center, fibroids are the primary reason for surgical removal of the uterus, accounting for approximately one-third of hysterectomies performed annually in the U.S.

MRgFUS represents a noninvasive, outpatient alternative to hysterectomy. “This treatment is ideal for older women who have completed their families and have a single or limited number of fibroids,” said co-author Clare M. Tempany, M.D., professor of radiology at Harvard Medical School and director of Clinical Focused Ultrasound at Brigham and Women’s Hospital.

The researchers studied 160 women with symptomatic fibroids. The women received pre-treatment MR imaging to identify and define the target fibroids. Radiologists then used MRgFUS to locate and treat the targeted fibroids while monitoring temperature changes in tissue.
Ninety-six patients were treated under the original study protocol (A), and 64 patients were treated under an optimized protocol (B). Protocol A allowed a maximum treatment time of 120 minutes and a maximum fibroid treatment volume of 100ccs (roughly six centimeters (cm) in diameter), or up to 33 percent of total fibroid volume. Protocol B allowed a maximum treatment time of 180 minutes and maximum fibroid treatment volume of 150ccs (about seven cm in diameter), or up to 33 percent of total volume in subserosal fibroids (those on the outer wall of the uterus) and 50 percent of volume in non-subserosal fibroids.

“Through this study, we’ve learned that MRgFUS can be optimized with newer protocols to have even better results than previously thought possible,” Dr. Tempany said.

The findings showed significant symptom relief at three months and sustained relief at one year. Women treated with the optimized protocol reported greater symptom relief and quality of life improvement than those treated with the original protocol. No serious adverse effects were reported.

“We have shown that treating fibroids with an optimized, less restrictive protocol allows for treatment of a greater fibroid volume, which results in even greater symptomatic relief at clinical follow-up,” Dr. Fennessy said.

Source: RSNA Media Relations
Linda Brooks
1-630-590-7738
[email protected]

Related Content

SuperSonic Imagine Introduces Aixplorer Mach 30 Ultrasound at The Liver Meeting
Technology | Ultrasound Imaging | November 14, 2018
SuperSonic Imagine recently exhibited at The Liver Meeting, held Nov. 9-13 in San Francisco, where the company...
New Robotic Arm System Optimizes Testing of Ultrasound Probes

Image courtesy of Esaote

News | Ultrasound Imaging | November 09, 2018
Medical imaging company Esaote and The BioRobotics Institute of Scuola Superiore Sant’Anna in Pisa, Italy, have...
The Acuson Sequoia

The Acuson Sequoia from Siemens Healthineers.

Feature | Ultrasound Imaging | November 05, 2018 | By Jeff Zagoudis
As the world’s most utilized medical imaging modality, ultrasound is likely to be featured heavily at the 2018...
Fujifilm SonoSite Launches New Point-of-Care Ultrasound Educational Resources
News | Ultrasound Imaging | November 01, 2018
Fujifilm SonoSite Inc. announced the launch of its redesigned SonoSite Institute, a comprehensive online educational...
Vygon and Sonoscanner Partnering on New Ultrasound System for Catheter Placement Guidance
News | Cardiovascular Ultrasound | October 31, 2018
Vygon, an international group specialized in single-use medical devices, and French company Sonoscanner announced the...
Cardiac Ultrasound Software Streamlines Fetal Heart Exams
Feature | Cardiovascular Ultrasound | October 30, 2018
A new tool called fetalHQ on GE Healthcare’s Voluson ultrasound systems is the first tool to simultaneously examine the...
Hitachi Supports ASE Foundation Cardiovascular Outreach Mission in West Virginia
News | Cardiovascular Ultrasound | October 29, 2018
Hitachi Healthcare Americas participated in the cardiovascular screening and diagnostic triage event that took place...
Philips Debuts Integrated Breast Ultrasound Solution
News | Ultrasound Women's Health | October 26, 2018
Philips announced what it calls its ultimate ultrasound solution for breast assessment, available with the Philips Epiq...
Samsung Unveils New HERA Ultrasound Systems at ISUOG World Congress 2018

The HERA I10 ultrasound system on display at the ISUOG World Congress 2018. Image courtesy of Samsung Medison.

News | Ultrasound Imaging | October 24, 2018
Samsung Electronics affiliate Samsung Medison is showcasing its new generation of premium ultrasound systems — the HERA...
Nanosonics Trophon2 High Level Disinfection System Available in U.S. and Canada
Technology | Ultrasound Imaging | October 17, 2018
October 17, 2018 — Nanosonics announced the commercial availability of its Trophon2 high level disinfection (HLD) sys